» Articles » PMID: 12960356

Cytokine Milieu of Atopic Dermatitis, As Compared to Psoriasis, Skin Prevents Induction of Innate Immune Response Genes

Overview
Journal J Immunol
Date 2003 Sep 10
PMID 12960356
Citations 235
Authors
Affiliations
Soon will be listed here.
Abstract

Atopic dermatitis (AD) and psoriasis are the two most common chronic skin diseases. However patients with AD, but not psoriasis, suffer from frequent skin infections. To understand the molecular basis for this phenomenon, skin biopsies from AD and psoriasis patients were analyzed using GeneChip microarrays. The expression of innate immune response genes, human beta defensin (HBD)-2, IL-8, and inducible NO synthetase (iNOS) was found to be decreased in AD, as compared with psoriasis, skin (HBD-2, p = 0.00021; IL-8, p = 0.044; iNOS, p = 0.016). Decreased expression of the novel antimicrobial peptide, HBD-3, was demonstrated at the mRNA level by real-time PCR (p = 0.0002) and at the protein level by immunohistochemistry (p = 0.0005). By real-time PCR, our data confirmed that AD, as compared with psoriasis, is associated with elevated skin production of Th2 cytokines and low levels of proinflammatory cytokines such as TNF-alpha, IFN-gamma, and IL-1beta. Because HBD-2, IL-8, and iNOS are known to be inhibited by Th2 cytokines, we examined the effects of IL-4 and IL-13 on HBD-3 expression in keratinocyte culture in vitro. We found that IL-13 and IL-4 inhibited TNF-alpha- and IFN-gamma-induced HBD-3 production. These studies indicate that decreased expression of a constellation of antimicrobial genes occurs as the result of local up-regulation of Th2 cytokines and the lack of elevated amounts of TNF-alpha and IFN-gamma under inflammatory conditions in AD skin. These observations could explain the increased susceptibility of AD skin to microorganisms, and suggest a new fundamental rule that may explain the mechanism for frequent infection in other Th2 cytokine-mediated diseases.

Citing Articles

Systemic barrier dysfunction in type 2 inflammation diseases: perspective in the skin, airways, and gastrointestinal tract.

Meng J, Xiao H, Xu F, She X, Liu C, Canonica G Immunol Res. 2025; 73(1):60.

PMID: 40069459 PMC: 11897119. DOI: 10.1007/s12026-025-09606-9.


Beyond the dichotomy: understanding the overlap between atopic dermatitis and psoriasis.

Li M, Wang J, Liu Q, Liu Y, Mi W, Li W Front Immunol. 2025; 16:1541776.

PMID: 39995673 PMC: 11847814. DOI: 10.3389/fimmu.2025.1541776.


Phenotypic Shift during Treatment of Plaque Psoriasis with Ixekizumab.

Sulich-Moore C, Altman D J Clin Aesthet Dermatol. 2025; 17(11):32-33.

PMID: 39758219 PMC: 11694639.


Ruscus aculeatus extract promotes RNase 7 expression through ERK activation following inhibition of late-phase autophagy in primary human keratinocytes.

Ono S, Kawasaki A, Tamura K, Minegishi Y, Mori T, Ota N PLoS One. 2024; 19(12):e0314873.

PMID: 39625882 PMC: 11614269. DOI: 10.1371/journal.pone.0314873.


Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review.

Zheng Y, Ding R, Bu J Front Immunol. 2024; 15:1367099.

PMID: 38812522 PMC: 11133567. DOI: 10.3389/fimmu.2024.1367099.